Cardiac Amyloidosis: Clinical Features, Pathogenesis, Diagnosis, and Treatment

Overview

Journal Turk Patoloji Derg

Specialty Pathology

Date 2023 Dec 19

PMID 38111336

Authors

Asuman Argon

Deniz Nart

Funda Yilmazbarbet

Affiliations

Soon will be listed here.

Abstract

Cardiac amyloidosis is a type of amyloidosis that deserves special attention as organ involvement significantly worsens the prognosis. Cardiac amyloidosis can be grouped under three main headings: immunoglobulin light chain (AL) amyloidosis that is dependent on amyloidogenic monoclonal light chain production; hereditary Transthyretin (TTR) amyloidosis that results from accumulation of mutated TTR; and wild-type (non-hereditary) TTR amyloidosis formerly known as senile amyloidosis. Although all three types cause morbidity and mortality due to severe heart failure when untreated, they contain differences in their pathogenesis, clinical findings, and treatment. In this article, the clinical features, pathogenesis, diagnosis, and treatment methods of cardiac amyloidosis will be explained with an overview, and an awareness will be raised in the diagnosis of this disease.

Citing Articles

Hematological diseases and the heart.

Can F Turk J Med Sci. 2024; 54(7):1438-1446.

PMID: 39735486 PMC: 11673626. DOI: 10.55730/1300-0144.5929.

Cardiac Amyloidosis: State-of-the-Art Review in Molecular Pathology.

Salzillo C, Franco R, Ronchi A, Quaranta A, Marzullo A Curr Issues Mol Biol. 2024; 46(10):11519-11536.

PMID: 39451564 PMC: 11506355. DOI: 10.3390/cimb46100684.

Analysis and insights of cardiac amyloidosis: novel perception of rare diseases in cardiology.

Huang H, Liu Y, Chen X, Guo H, Yin Y, Ding M Am J Transl Res. 2024; 16(9):4534-4548.

PMID: 39398585 PMC: 11470321. DOI: 10.62347/KXHZ6884.

Exploring the anti‑oxidative mechanisms of in ameliorating myocardial fibrosis through network pharmacology and experiments.

Zhang L, Yin H, Xie Y, Zhang Y, Dong F, Wu K Mol Med Rep. 2024; 30(6).

PMID: 39370810 PMC: 11450433. DOI: 10.3892/mmr.2024.13338.

Advances in the Diagnosis and Management of Cardiac Amyloidosis: A Literature Review.

Llerena-Velastegui J, Zumbana-Podaneva K Cardiol Res. 2024; 15(4):211-222.

PMID: 39205961 PMC: 11349137. DOI: 10.14740/cr1664.

References

Addison D, Slivnick J, Campbell C, Vallakati A, Jneid H, Schelbert E . Recent Advances and Current Dilemmas in the Diagnosis and Management of Transthyretin Cardiac Amyloidosis. J Am Heart Assoc. 2021; 10(9):e019840. PMC: 8200718. DOI: 10.1161/JAHA.120.019840. View

Muchtar E, Gertz M, Kyle R, Lacy M, Dingli D, Leung N . A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry-Verified Typing. Mayo Clin Proc. 2019; 94(3):472-483. DOI: 10.1016/j.mayocp.2018.08.006. View

Nativi-Nicolau J, Maurer M . Amyloidosis cardiomyopathy: update in the diagnosis and treatment of the most common types. Curr Opin Cardiol. 2018; 33(5):571-579. DOI: 10.1097/HCO.0000000000000547. View

Larsen B, Mereuta O, Dasari S, Fayyaz A, Theis J, Vrana J . Correlation of histomorphological pattern of cardiac amyloid deposition with amyloid type: a histological and proteomic analysis of 108 cases. Histopathology. 2015; 68(5):648-56. DOI: 10.1111/his.12793. View

Ng B, Connors L, Davidoff R, Skinner M, Falk R . Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis. Arch Intern Med. 2005; 165(12):1425-9. DOI: 10.1001/archinte.165.12.1425. View

Vaidya G, Patel J, Kittleson M, Chang D, Kransdorf E, Geft D . Intermediate-term outcomes of heart transplantation for cardiac amyloidosis in the current era. Clin Transplant. 2021; 35(6):e14308. DOI: 10.1111/ctr.14308. View

Schonland S, Hegenbart U, Bochtler T, Mangatter A, Hansberg M, Ho A . Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients. Blood. 2011; 119(2):488-93. DOI: 10.1182/blood-2011-06-358507. View

Mishra S, Guan J, Plovie E, Seldin D, Connors L, Merlini G . Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish. Am J Physiol Heart Circ Physiol. 2013; 305(1):H95-103. PMC: 3727100. DOI: 10.1152/ajpheart.00186.2013. View

Tanskanen M, Peuralinna T, Polvikoski T, Notkola I, Sulkava R, Hardy J . Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med. 2008; 40(3):232-9. DOI: 10.1080/07853890701842988. View

10.

Jacobson D, Pastore R, Yaghoubian R, Kane I, Gallo G, BUCK F . Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med. 1997; 336(7):466-73. DOI: 10.1056/NEJM199702133360703. View

11.

Dubrey S, Mendes L, Skinner M, Falk R . Resolution of heart failure in patients with AL amyloidosis. Ann Intern Med. 1996; 125(6):481-4. DOI: 10.7326/0003-4819-125-6-199609150-00009. View

12.

Maurer M, Schwartz J, Gundapaneni B, Elliott P, Merlini G, Waddington-Cruz M . Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2018; 379(11):1007-1016. DOI: 10.1056/NEJMoa1805689. View

13.

Santarone M, Corrado G, Tagliagambe L, Manzillo G, Tadeo G, Spata M . Atrial thrombosis in cardiac amyloidosis: diagnostic contribution of transesophageal echocardiography. J Am Soc Echocardiogr. 1999; 12(6):533-6. DOI: 10.1016/s0894-7317(99)70091-x. View

14.

Kyle R . Amyloidosis: a convoluted story. Br J Haematol. 2001; 114(3):529-38. DOI: 10.1046/j.1365-2141.2001.02999.x. View

15.

Mankad A, Shah K . Transthyretin Cardiac Amyloidosis. Curr Cardiol Rep. 2017; 19(10):97. DOI: 10.1007/s11886-017-0911-5. View

16.

Rubin J, Maurer M . Cardiac Amyloidosis: Overlooked, Underappreciated, and Treatable. Annu Rev Med. 2020; 71:203-219. DOI: 10.1146/annurev-med-052918-020140. View

17.

Stewart T . On the Waxy or Amyloid Form of Bright's Disease. Edinb Med J. 2018; 6(8):710-728. PMC: 5307054. View

18.

Falk R, Alexander K, Liao R, Dorbala S . AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy. J Am Coll Cardiol. 2016; 68(12):1323-41. DOI: 10.1016/j.jacc.2016.06.053. View

19.

Gonzalez-Lopez E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral F, Cobo-Marcos M, Robles C . Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015; 36(38):2585-94. DOI: 10.1093/eurheartj/ehv338. View

20.

Brenner D, Jain M, Pimentel D, Wang B, Connors L, Skinner M . Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res. 2004; 94(8):1008-10. DOI: 10.1161/01.RES.0000126569.75419.74. View